Prostate cancer (metastatic, hormone-relapsed) - enzalutamide [ID683]: committee papers

Table of Contents

 

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer - Astellas

03 - NICE request to the manufacturer for clarification on their submission

04 - Manufacturer clarification response

05 - Consultee submission - Prostate Cancer UK

06 - Consultee submission - Tackle Prostate Cancer

07 - Consultee submission - British Association of Urological Nurses

08 - Consultee submission - British Association of Urological Surgeons

09 - Consultee submission - British Uro-Oncology Group

10 - Consultee submission - NCRI RCP RCR ACP

11 - clinical expert personal perspective - CLARKE

12 - clinical expert personal perspective - JAIN

13 - clinical expert personal perspective - GUNN

14 - clinical expert personal perspective - WATSON

15 - Evidence Review Group report prepared by Aberdeen Health Technology Assessment Group

16 - Evidence Review Group report erratum

17 - Manufacturer factual accuracy check of Evidence Review Group report

This page was last updated: 09 June 2015